📰 Paul Audhya News

Paul Audhya News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Paul Audhya. Real-time updates on events, politics, business and more.

Oral Drug Gains Steam as On-Demand Option for Hereditary Angioedema Attacks

February 28, 2024

Investigational sebetralstat offered symptom relief in under 2 hours

United States Paul Audhya Kalvista Pharmaceuticals In Cambridge American Academy Of Allergy Kalvista Pharmaceuticals American Academy

Source: medpagetoday.com

KalVista Pharmaceuticals to Present Phase 3 Sebetralstat Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting

February 16, 2024

– Late-breaking phase 3 data for KONFIDENT trial on Sunday, February 25, 2024 – ...

United States Maeve Oconnor William Lumry Markus Heckmann Matthew Iverson Cristine Radojicic

Source: marketscreener.com

KalVista Pharmaceuticals to Present Phase 3 Sebetralstat Data at the 2024 American Academy of Allerg

February 16, 2024

– Late-breaking phase 3 data for KONFIDENT trial on Sunday, February 25, 2024 –CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--$KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule pro...

United Kingdom United States Mashonaland East Paul Audhya Maeve Oconnor Neil Malloy

Source: pharmiweb.com

KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals to Present Data at the 13th C1-inhibitor Deficiency & Angioedema Workshop

April 27, 2023

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today

Erik Hansen Matthew Iverson Sally Van Kooten Studyvibha Desai Sallyl Hampton Michaeld Smith

Source: finanznachrichten.de

KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals to Present Data on Oral On-Demand HAE Therapy KVD900 at AAAAI 2022

February 2, 2022

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today

United States Edwardj Duckworth Ben Palleiko Exchange Commission Kalvista Pharmaceuticals Inc American Academy Of Allergy

Source: finanznachrichten.de

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science

Navigation